Adverum Biotechnologies, Inc. (ADVM)
Dec 9, 2025 - ADVM was delisted (reason: acquired by LLY)
4.360
+0.100 (2.35%)
Inactive · Last trade price on Dec 8, 2025
Adverum Biotechnologies Stock Forecast
Stock Price Forecast
The 5 analysts with 12-month price forecasts for Adverum Biotechnologies stock had an average target of 11.6, with a low estimate of 4.00 and a high estimate of 33.
Price Target: $11.6 (+166.06%)
Analyst Consensus: Buy
* Price targets were last updated on Nov 17, 2025.
Analyst Ratings
The average analyst rating for Adverum Biotechnologies stock from 5 stock analysts was "Buy". This means that analysts believed this stock was likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Jul '25 | Aug '25 | Sep '25 | Oct '25 | Nov '25 | Dec '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 3 | 3 | 2 | 2 | 1 | 1 |
| Buy | 1 | 1 | 1 | 1 | 1 | 1 |
| Hold | 1 | 1 | 1 | 2 | 3 | 3 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 5 | 5 | 4 | 5 | 5 | 5 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy → Hold Downgrades $30 → $5 | Strong Buy → Hold | Downgrades | $30 → $5 | +14.68% | Nov 17, 2025 |
| RBC Capital | RBC Capital | Hold Maintains $3 → $4 | Hold | Maintains | $3 → $4 | -8.26% | Oct 28, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $30 | Strong Buy | Reiterates | $30 | +588.07% | Sep 23, 2025 |
| Chardan Capital | Chardan Capital | Strong Buy Maintains $33 | Strong Buy | Maintains | $33 | +656.88% | Aug 13, 2025 |
| Mizuho | Mizuho | Buy Maintains $16 → $12 | Buy | Maintains | $16 → $12 | +175.23% | Jun 26, 2025 |
Financial Forecast
Revenue This Year
12.92M
from 1.00M
Increased by 1,192.00%
Revenue Next Year
255.00K
from 12.92M
Decreased by -98.03%
EPS This Year
-6.66
from -6.62
EPS Next Year
-3.67
from -6.66
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | 78.8M | 1.1M | ||||
| Avg | 12.9M | 255,000 | ||||
| Low | n/a | n/a |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | 7,775.0% | -91.9% | ||||
| Avg | 1,192.0% | -98.0% | ||||
| Low | - | - |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | -3.72 | -0.56 | ||||
| Avg | -6.66 | -3.67 | ||||
| Low | -8.58 | -8.08 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | - | - | ||||
| Avg | - | - | ||||
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.